How monoHER helps cancer cells respond better to doxorubicin
Author Information
Author(s): Hilde Jacobs, A. Bast, G. J. Peters, W. J. F. van der Vijgh, G. R. M. M. Haenen
Primary Institution: Maastricht University Medical Centre+
Hypothesis
Does monoHER enhance the effectiveness of doxorubicin in treating soft tissue sarcoma cells?
Conclusion
MonoHER enhances the effectiveness of doxorubicin by reducing its activation of NF-κB, which helps cancer cells undergo apoptosis.
Supporting Evidence
- MonoHER increased the apoptosis in WLS-160 cells when combined with doxorubicin.
- MonoHER did not affect intracellular GSH levels.
- MonoHER significantly reduced doxorubicin-induced NF-κB activation.
Takeaway
This study found that a compound called monoHER can help a cancer drug called doxorubicin work better by making cancer cells more likely to die.
Methodology
The study involved treating human soft tissue sarcoma cell lines with monoHER and doxorubicin, followed by assays to measure cell growth inhibition, apoptosis, and NF-κB activation.
Potential Biases
Potential bias due to the small sample size and the specific cell line used.
Limitations
The study was limited to a small number of patients and cell lines, which may not represent all soft tissue sarcomas.
Participant Demographics
Patients with metastatic soft tissue sarcoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website